Plain-English reading on the vagus nerve, its science and how to look after it
Conditions

The Impact of the Vagus Nerve on Migraine Headaches

A flat folk-art illustration of a human head in profile set between mirrored sprays of marigolds, small blossoms and fern fronds.

Migraine affects roughly one billion people worldwide and ranks among the leading causes of disability. For decades, treatment focused on the pain itself — triptans to constrict blood vessels, NSAIDs to blunt inflammation, and preventive drugs borrowed from epilepsy and cardiovascular medicine. The vagus nerve has emerged as a different kind of target. Rather than acting on a single receptor, vagus nerve stimulation (VNS) modulates the brainstem circuits that initiate and sustain migraine attacks, offering a non-drug option with a mechanism distinct from anything in the pharmacy.

The Trigeminovascular System and the Vagus Nerve

Migraine is driven by the trigeminovascular system, a network of sensory neurons whose cell bodies sit in the trigeminal ganglion and whose fibres innervate the meningeal blood vessels surrounding the brain. When these fibres are activated — by cortical spreading depression, chemical triggers, or mechanisms not yet fully understood — they release calcitonin gene-related peptide (CGRP) and other neuropeptides at the meningeal vessels, producing neurogenic inflammation: vasodilation, plasma protein extravasation, and sensitisation of surrounding pain fibres.

The vagus nerve enters this picture at the brainstem. Vagal afferents from the ear, throat, and viscera terminate in the nucleus tractus solitarius (NTS), which sits adjacent to the trigeminal nucleus caudalis (TNC) — the brainstem relay station where trigeminovascular pain signals are processed. The NTS and TNC share interneuronal connections, and vagal input can modulate trigeminal pain processing through both direct inhibition and descending pain-control pathways involving the periaqueductal grey, locus coeruleus, and raphe nuclei.

This anatomical convergence means that stimulating the vagus nerve can dampen the brainstem circuits that amplify migraine pain, without needing to reach the trigeminal nerve directly. It also means the vagus nerve can influence the autonomic symptoms that accompany many migraines — nausea, changes in heart rate, facial flushing — because these are mediated through the same brainstem nuclei.

CGRP: The Molecular Target That Connects VNS to Migraine

The discovery that CGRP is a central driver of migraine transformed both drug development and our understanding of how VNS works. During a migraine attack, CGRP levels rise in the jugular venous blood. Intravenous CGRP infusion reliably triggers migraine in susceptible individuals. This led to the development of anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and small-molecule CGRP receptor antagonists (gepants such as ubrogepant and rimegepant), which have become first-line preventive and acute treatments.

Vagus nerve stimulation appears to reduce CGRP release through its action on the NTS and descending inhibitory pathways. Animal studies show that VNS suppresses trigeminal neuronal firing and reduces markers of neurogenic inflammation in the meninges. This gives VNS a mechanistic rationale that parallels the anti-CGRP drugs but works through a neural circuit rather than a molecular blockade — a distinction that matters for patients who cannot tolerate or do not respond to CGRP-targeted medications.

Your local vagus nerve experts

Find a vagus nerve practitioner near you

Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.

Or browse by approach

The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.

gammaCore: Non-Invasive Vagus Nerve Stimulation for Migraine

The gammaCore device, developed by electroCore, delivers non-invasive vagus nerve stimulation (nVNS) through the skin of the neck over the cervical vagus nerve. The device received FDA clearance for the acute treatment of episodic cluster headache in 2017, and for migraine (both acute treatment and prevention) in subsequent clearances. It is applied to the neck for two-minute stimulation cycles, typically two to three cycles per treatment.

Acute Treatment Evidence

The PRESTO trial, a double-blind, sham-controlled study of 243 patients with episodic migraine, evaluated nVNS for acute treatment of migraine attacks. At 30 minutes after treatment, 12.7 percent of patients in the nVNS group were pain-free compared to 4.2 percent in the sham group, with an odds ratio of 2.3. At 60 minutes, the pain-free rate for nVNS rose to 21.0 percent versus 10.0 percent for sham. Response rates (at least 50 percent pain reduction) were also significantly higher in the nVNS group. While these absolute numbers are modest compared to triptans, they represent a meaningful effect for a non-pharmacological treatment with minimal side effects.

Preventive Treatment Evidence

The EVENT trial, an open-label study of 59 patients with chronic migraine, evaluated nVNS as a preventive treatment administered twice daily. Over the treatment period, patients experienced a reduction of 3.6 to 6.0 fewer headache days per month compared to baseline, depending on the analysis timeframe. A separate study of 56 women with menstrual migraine found that prophylactic nVNS reduced headache days from 7.2 to 4.7 per cycle, with a 39 percent responder rate (defined as at least 50 percent reduction in headache days).

Practical Considerations

The gammaCore device requires a prescription and uses a proprietary refill model. Each treatment consists of placing the device on the neck and delivering a two-minute stimulation. For acute use, the manufacturer recommends three consecutive stimulations at migraine onset. For prevention, two stimulations morning and evening. The most common side effects are mild: local skin irritation, tingling, and occasional neck discomfort. There are no systemic drug interactions, making nVNS particularly suitable for patients on multiple medications, pregnant women (for whom most migraine drugs are contraindicated), or those with medication-overuse headache.

How VNS Compares to Other Migraine Treatments

VNS occupies a specific niche in the migraine treatment landscape. It is not a replacement for triptans in patients who respond well to them — triptans produce pain-free rates of 25 to 35 percent at two hours, roughly double what nVNS achieves. However, VNS offers advantages that pharmacological treatments cannot match.

Unlike triptans, nVNS carries no risk of medication-overuse headache (rebound headache), a condition where frequent use of acute migraine drugs paradoxically increases headache frequency. This makes nVNS suitable for patients who experience frequent attacks and risk overusing acute medications. Unlike anti-CGRP antibodies, nVNS has no immunological mechanism and no concerns about long-term effects on the vascular or immune systems. Unlike preventive medications such as topiramate or valproate, nVNS produces no cognitive side effects, weight changes, or teratogenicity.

For many patients, the most practical approach is combining nVNS with pharmacological treatments. VNS can be used as a first-line acute treatment for mild to moderate attacks, reserving triptans for more severe episodes. This strategy reduces triptan consumption and may help prevent medication-overuse headache while providing comprehensive attack coverage.

Emerging Research: Closed-Loop and Auricular Approaches

Current nVNS devices deliver stimulation at fixed parameters regardless of the patient’s physiological state. Closed-loop VNS systems, under development, would monitor physiological markers — such as heart rate variability, electrodermal activity, or even EEG patterns — and deliver stimulation automatically when a migraine is detected or predicted. This approach could intervene during the prodromal phase, before pain begins, potentially improving efficacy while reducing unnecessary stimulation.

Transcutaneous auricular VNS (taVNS), which stimulates the auricular branch of the vagus nerve in the ear, is also being investigated for migraine. The ear-based approach targets a different branch of the vagus nerve than cervical nVNS, and early studies suggest it may have distinct effects on brainstem processing. Several randomised trials are evaluating taVNS for both acute and preventive migraine treatment, though the evidence base is less mature than for cervical nVNS.

The Gut-Brain Axis in Migraine

An emerging area of research connects migraine to the gut-brain axis, with the vagus nerve as the primary communication channel. Migraine patients show higher rates of irritable bowel syndrome, gastroparesis, and other GI disorders than the general population. The vagus nerve carries sensory information from the gut to the brainstem, and inflammatory signals from the gut can sensitise the trigeminal system through this pathway.

Some researchers propose that vagus nerve stimulation may benefit migraine in part by modulating gut-brain signalling — reducing visceral inflammation, normalising gastric motility (which is often disrupted during migraine attacks), and shifting the balance of gut-derived neurotransmitter precursors. While this remains largely theoretical, it aligns with clinical observations that many migraine patients report GI improvement alongside headache reduction during VNS treatment.

Practical Guidance

If you experience migraines and are considering VNS, several factors can help guide the decision. VNS is particularly worth considering if you experience frequent migraines that put you at risk for medication-overuse headache, if you have not responded adequately to or cannot tolerate standard preventive medications, if you are pregnant or planning pregnancy and need a non-pharmacological option, or if you prefer a drug-free approach to migraine management.

VNS is not a cure for migraine, and the response rates, while statistically significant, are modest compared to the best pharmacological options. It works best as part of a comprehensive migraine management plan that includes trigger identification, lifestyle modification, and appropriate use of acute and preventive medications when needed. A headache specialist or neurologist can help determine whether VNS fits within your overall treatment strategy.

For a deeper understanding of the vagus nerve’s role in pain, neurological health, and whole-body regulation, the Vagus Nerve & Me eBook provides a science-grounded guide to how this single nerve connects brain, gut, heart, and immune system. Get My Vagus Nerve & Me eBook and explore practical strategies for supporting your vagal health.

Related concerns

This article is for general information and is not medical advice. Talk to a qualified clinician before changing anything about your health or treatment. Read our medical disclaimer. Spotted an error? Let us know.